Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
Conditions
Keywords
cancer, AT-101, AT101, B-cell malignancies, Non-Hodgkin, lymphoma, lukemia
Brief summary
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.
Detailed description
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies. For the purpose of this study, B-cell malignancies can include one of the following disease sub-types: follicular lymphoma (FL), diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia. Patients will be enrolled according to disease subtype into one of four groups in two stages. The first stage of each group will enrolled 13 patients. If patients within any group experience disease response, an additional 14 patients will be enrolled into that group.
Interventions
DRUGAT-101
Oral
Sponsors
Ascenta Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must have a histologically confirmed B-cell malignancy (defined as FL \[any grade\], DLBCL, MCL or SLL/CLL); * Male or non-pregnant, non-lactating females age ≥18 years; * Ability to swallow and retain oral medication.; * Have failed at least one prior therapy and have documentation of either, relapsed disease, or refractory disease (i.e., no response or stable disease on their last regimen of therapy); * ECOG performance status 0 or 1; * All clinically significant toxicities from prior therapy must have fully resolved; * Must have discontinued treatment with monoclonal antibodies for a minimum of 90 days prior to first dose of AT-101, or have objective documentation of disease progression if within 90 days of monoclonal antibody administration; * Patients with FL, DLBCL, MCL, and SLL with normal lymphocyte counts must have at least one bi-dimensional lesion that is radiographically measurable (skin lesions, palpable lymph nodes, and bone marrow as the only site of disease are not considered measurable disease); * Patients with SLL whose lymphocytes are elevated at baseline or CLL must have palpable lymph nodes and/or disease localized to the bone marrow per the NCI-Sponsored Working Group Guidelines for CLL.
Exclusion criteria
* Requirement of systemic corticosteroids within 7 days prior to and during AT-101 administration; * Must not have received anti-cancer therapy within 28 days of first dose of AT-101. Cannot have received hormonal agents or biologic dose modifiers (with the exception of HRT) or any investigational treatments within 28 days of treatment with AT-101; * Patients with CNS lymphoma, HIV-related lymphoma, symptoms suggesting HIV infection or active auto-immune hemolytic anemia are excluded; * Previous treatment with gossypol, or are hypersensitive to its excipient are excluded; * Patients who have an uncontrolled, concurrent illness are also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete or partial remission of disease. | every 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events. | every 3 weeks |
| duration of response | every 6 weeks |
Countries
United States
Outcome results
None listed